Fierce Biotech Unveils 2026 Fierce 15: A Focus on Fertility, Oncology, and AI

Key points

• Fierce Biotech's 2026 Fierce 15 list recognizes 15 private biotech companies for their innovative science and potential to shape next-generation medicines.
• Alveus Therapeutics, founded in 2023, focuses on obesity and metabolic diseases, with lead candidate ALV-100 targeting long-term weight maintenance rather than just weight loss.
• Beacon Therapeutics, based in London, is developing laru-zova, a gene therapy for X-linked retinitis pigmentosa, after positive phase 3 data in September 2026.
• EpiBiologics, based in San Mateo, California, is using bispecific antibodies to degrade membrane and extracellular proteins, with lead candidate EPI-326 in phase 1 trials for solid tumors.
• Expedition Medicines, founded by Flagship Pioneering, uses AI and covalent chemistry to develop small molecules for previously 'undruggable' targets, with a partnership with Pfizer for prostate cancer.
• Freya Biosciences, based in Copenhagen, is developing therapies to reprogram the female microbiome for reproductive health, with lead candidate FB301 in phase 2 for IVF implantation failure.

Background

The 2026 Fierce 15 list comes at a time when the biotech sector is recovering financially, with venture capital funding in Massachusetts rising 25% year-over-year in H1 2026. This recovery is reflected in the significant funding rounds and partnerships secured by several Fierce 15 companies, such as Alveus Therapeutics' $197 million series A and Infinimmune's $75 million series A. The list also highlights a growing focus on unmet medical needs, such as fertility and women's health, which have historically lagged behind other areas in therapeutic development. The Fierce 15 list is part of a broader trend of recognizing innovative biotech companies, with other lists like the Endpoints 11 and Fierce 50 also highlighting companies and leaders making significant contributions to the industry.

How outlets are covering it

Fierce Biotech emphasizes the innovative science and potential of the 2026 Fierce 15 companies to shape next-generation medicines. Yahoo Finance and GlobeNewswire highlight the recognition of specific companies like SonoThera and ReproNovo, respectively, as part of the Fierce 15 list. The Manila Times focuses on Freya Biosciences' inclusion in the list, highlighting its work in reproductive health. These perspectives reflect the diverse therapeutic areas and innovative approaches of the Fierce 15 companies, as well as the growing momentum in the biotech sector.

Why it matters

The 2026 Fierce 15 list highlights the innovative approaches and potential of private biotech companies to address unmet medical needs. The companies on the list are developing therapies for a wide range of conditions, including obesity, eye disease, oncology, immunology, reproductive health, and hair loss. The list also reflects a broader industry trend of capital returning to early-stage biotech, with several companies securing significant funding rounds and partnerships with major pharmaceutical firms. This trend is expected to drive further innovation and development in the biotech sector, potentially leading to new treatments and therapies for patients.

What to watch

Several Fierce 15 companies are expected to advance their lead candidates into later-stage clinical trials in the coming months. Alveus Therapeutics expects to have its lead candidate ALV-100 in phase 3 trials by 2028. Beacon Therapeutics plans to seek approval for laru-zova using its phase 3 data. EpiBiologics is considering expanding its phase 1 trial of EPI-326 into colorectal cancer. Freya Biosciences expects to enter phase 2 development for FB401 in the third quarter of 2027. Infinimmune is gearing up to launch phase 1 studies of its lead monoclonal antibodies IFX-101 and IFX-201 in Australia next year. Neomorph plans to take another drug into human testing next year, followed by a third in 2028. Nuclidium is supporting phase 1/2 trials for its lead theranostics NU101 and NU201. Pelage Pharmaceuticals is developing a treatment for hair loss by activating stem cells. ReproNovo is advancing its pipeline with clinical trials currently ongoing in the U.S., Europe, and China.